Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

PURPOSE: We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM). PATIENTS AND METHODS: A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Treon, Steven P., Ioakimidis, Leukothea, Soumerai, Jacob D., Patterson, Christopher J., Sheehy, Patricia, Nelson, Marybeth, Willen, Michael, Matous, Jeffrey, Mattern, John, Diener, Jakow G., Keogh, George P., Myers, Thomas J., Boral, Andy, Birner, Ann, Esseltine, Dixie L., Ghobrial, Irene M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727288/
https://ncbi.nlm.nih.gov/pubmed/19506160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.4677
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados